Takeaway

• The results of this network meta-analysis suggest that the best choice for first-line advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab.
• Regorafenib and cabozantinib are best in refractory disease.

Why this matters

• The results suggest that these options should be the standard of care in the respective settings. 

Study design

• Network...